Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

National uniformity for OTCs should be a priority in 105th Congress, Sen. Hatch says.

This article was originally published in The Tan Sheet

Executive Summary

NATIONAL UNIFORMITY FOR OTC DRUGS should be a priority in the 105th Congress, Sen. Orrin Hatch (R-Utah) said in a Sept. 30 floor statement on FDA reform efforts in the 104th session. "[An] issue that I would like to see addressed next year is one that has been periodically on the FDA radar screen -- the issue of national uniformity in regulation of products that fall within FDA's purview," Hatch stated.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086199

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel